Filing Flows › Idexx Laboratories (IDXX) › Guidance & outlook
Idexx Laboratories (IDXX) guidance and outlook
Idexx Laboratories (IDXX) raised some and lowered other parts of its guidance on Nov 2, 2026: Revenue $4.7B–$4.8B for FY2026; Revenue +10.1% to +10.8% for FY2026; EPS $14.96–$15.16 for FY2026; Operating margin 32.1%–32.3% for FY2026. Idexx Laboratories' 10-Q filed Nov 2, 2026 makes 2 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $4.7B–$4.8B | raised |
| Revenue | FY2026 | +10.1% to +10.8% | raised |
| Revenue | FY2026 | +11% to +11.7% | new |
| Revenue | FY2026 | +9.3% to +10% | raised |
| EPS | FY2026 | $14.96–$15.16 | raised |
| Operating margin | FY2026 | 32.1%–32.3% | lowered |
| Operating margin | FY2026 | +50 bps to +70 bps | lowered |
| EPS | FY2026 | +15% | raised |
| Operating margin | FY2026 | 32.1%–32.3% | lowered |
| Interest expense | FY2026 | $32.0M | lowered |
| Stock-based compensation | FY2026 | $19.0M | raised |
| Tax rate | FY2026 | 1.3% | reaffirmed |
From the earnings release filed Nov 2, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 2, 2026
- We anticipate reductions in share-based compensation tax benefits during the three months ending December 31, 2026, compared to the same period in the prior year, which increases our future effective tax rate.
- We anticipate funding the full repayment of our 2027 Series B Notes for $75.0 million when due on February 12, 2027, with available cash on hand, borrowings under our Credit Facility, proceeds from the issuance of new notes, or a combination thereof.
Idexx Laboratories' latest quarter
Idexx Laboratories, Q3 2026: revenue $1.2B (+10% year over year), operating margin 33.1%, net earnings $317M, operating cash flow $450M. The chart follows the revenue to costs, profit and cash.
Questions
Did Idexx Laboratories raise or lower its guidance?
Idexx Laboratories (IDXX) raised some and lowered other parts of its guidance on Nov 2, 2026: Revenue $4.7B–$4.8B for FY2026; Revenue +10.1% to +10.8% for FY2026; EPS $14.96–$15.16 for FY2026; Operating margin 32.1%–32.3% for FY2026.
What does Idexx Laboratories expect?
We anticipate reductions in share-based compensation tax benefits during the three months ending December 31, 2026, compared to the same period in the prior year, which increases our future effective tax rate. We anticipate funding the full repayment of our 2027 Series B Notes for $75.0 million when due on February 12, 2027, with available cash on hand, borrowings under our Credit Facility, proceeds from the issuance of new notes, or a combination thereof.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.